Recent studies have revealed that CDX2 is aberrantly expressed in gastric cancer, colorectal cancer, thyroid cancer, ovarian cancer, endometrial adenocarcinoma, bladder and prostate adenocarcinoma [26, 27]. Here, CDX2 is linked to prostate adenocarcinoma.